Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma

Summary

This is a phase I study to observe the safety and efficacy of irinotecan and bevacizumab combined with re-radiotherapy in the treatment of recurrent glioblastoma. The study will provide a higher level of clinical evidence-based evidence for the clinical treatment of recurrent GBM, and fill the guidelines for the treatment of recurrent GBM.

Timeline

Start

2021-12-22

Primary completion

2022-12-20

Completion

2024-12-20

Drugs

Indications